Postdoctoral Researcher at Oniria Therapeutics S.L./UCLA

Oniria Therapeutics is a biopharmaceutical company in the field of precision oncology focused on cancer persistence. Oniria Therapeutics aims to revolutionize cancer treatment by bringing to market the first-in-class drug ONR-001, designed for solid and aggressive liquid tumors unresponsive to current treatments, paving the way for novel therapeutic combinations or standalone treatments. Oniria has develop small drugs targeting factors relevant for other diseases beyond cancer, and is willing to explore their potency as new therapeutic agents for aging-related diseases.

The company was founded in 2021 as a Spin-off of the Vall d’Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and Catalan Institution for Research and Advanced Studies (ICREA).

The Ebru Laboratory, at the University of California, Los Angeles (UCLA), is a cutting-edge research facility focused on advancing precision medicine in the field of cardiovascular diseases and aging. The laboratory aims to transform the understanding and treatment of cardiovascular conditions by exploring novel therapeutic approaches, with an emphasis on dyslipidemia and other related disorders. Through innovative research and collaborative efforts, the laboratory seeks to develop groundbreaking treatments that address cardiovascular diseases that are resistant to current therapies, laying the foundation for future treatment options and improvements in patient care. This central aim is shared with Oniria Therapeutics and its new drugs.

We are seeking a motivated Postdoctoral Researcher to join the Ebru Laboratory (UCLA) during a 2-3 years post-doctoral stage.. This position offers an exciting opportunity to initiate a new line of collaborative research focused on treating dyslipidemia and cardiovascular diseases using Oniria Therapeutics’ first-in-class drugs. The candidate will participate in an international and highly translational project with interactions with academic institutions, industry and clinicians.